Tamoxifen

• 

  Subject Areas on Research

  • 17beta-Estradiol inhibits Ca2+-dependent homeostasis of airway surface liquid volume in human cystic fibrosis airway epithelia. 
  • A negative coregulator for the human ER. 
  • A next-generation dual-recombinase system for time- and host-specific targeting of pancreatic cancer. 
  • A parametric model for long-term follow-up data from phase III breast cancer clinical trials. 
  • A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A tamoxifen inducible knock-in allele for investigation of E2A function. 
  • ALSUntangled 59: Tamoxifen. 
  • Acquired thrombotic risk factors in the critical care setting. 
  • Activation of Rod Input in a Model of Retinal Degeneration Reverses Retinal Remodeling and Induces Formation of Functional Synapses and Recovery of Visual Signaling in the Adult Retina. 
  • Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 
  • Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. 
  • American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. 
  • Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. 
  • Anti-estrogenic compounds increase prolactin and growth hormone synthesis in clonal strains of rat pituitary cells. 
  • Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. 
  • Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease. 
  • Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. 
  • BRCA1 expression is not directly responsive to estrogen. 
  • Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. 
  • Biphasic functions for the GDNF-Ret signaling pathway in chemosensory neuron development and diversification. 
  • Breast Cancer Risk-Reducing Medications. 
  • Breast cancer anxiety's associations with responses to a chemoprevention decision aid. 
  • Breast cancer in older women. 
  • Breast cancer. Clinical practice guidelines in oncology. 
  • Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. 
  • Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression. 
  • Cell cycle regulation of human pancreatic cancer by tamoxifen. 
  • Cell lineage mapping of taste bud cells and keratinocytes in the mouse tongue and soft palate. 
  • Circumventing tamoxifen resistance in breast cancers using antiestrogens that induce unique conformational changes in the estrogen receptor. 
  • Communicating side effect risks in a tamoxifen prophylaxis decision aid: the debiasing influence of pictographs. 
  • Comparative analyses of mechanistic differences among antiestrogens. 
  • Complexity in endometrial estradiol signaling. 
  • Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. 
  • Dedifferentiation of committed epithelial cells into stem cells in vivo. 
  • Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. 
  • Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. 
  • Development of an ER action indicator mouse for the study of estrogens, selective ER modulators (SERMs), and Xenobiotics. 
  • Development of peptide antagonists that target estrogen receptor-cofactor interactions. 
  • Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements. 
  • Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ. 
  • Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone. 
  • Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis? 
  • ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention. 
  • Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907. 
  • Effect of vitamin E on tamoxifen-treated breast cancer cells. 
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. 
  • Effects of chemotherapy and tamoxifen on cervical and vaginal smears in bone marrow transplant recipients. 
  • Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer. 
  • Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. 
  • Endocrine therapy in metastatic breast cancer. 
  • Estimation and testing of the relative risk of disease in case-control studies with a set of k matched controls per case with known prevalence of disease. 
  • Estrogen modulation of nuclear matrix-associated steroid hormone binding. 
  • Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. 
  • Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo. 
  • Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. 
  • Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. 
  • Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. 
  • Expression level is a key determinant of E2F1-mediated cell fate. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). 
  • G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. 
  • Gut stem cell aging is driven by mTORC1 via a p38 MAPK-p53 pathway. 
  • Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. 
  • How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. 
  • Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. 
  • Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. 
  • Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. 
  • Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of the Cancer Risk Intake System on patient-clinician discussions of tamoxifen, genetic counseling, and colonoscopy. 
  • Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injury. 
  • Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. 
  • Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. 
  • Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. 
  • Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. 
  • Juvenile fibromatosis: hormonal receptors. 
  • Ligand-selective interactions of ER detected in living cells by fluorescence resonance energy transfer. 
  • Lineage-specific laminar organization of cortical GABAergic interneurons. 
  • Management of ductal carcinoma in situ. 
  • Methods to generate genetically engineered mouse models of soft tissue sarcoma. 
  • Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. 
  • Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons. 
  • Moderate heart dysfunction in mice with inducible cardiomyocyte-specific excision of the Serca2 gene. 
  • Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. 
  • Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy. 
  • Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. 
  • Patient and provider determinants associated with the prescription of adjuvant hormonal therapies following a diagnosis of breast cancer in Medicaid-enrolled patients. 
  • Peptide antagonists of the human estrogen receptor. 
  • Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen. 
  • Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. 
  • Plasticity of Hopx(+) type I alveolar cells to regenerate type II cells in the lung. 
  • Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. 
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. 
  • Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? 
  • Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. 
  • Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. 
  • Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. 
  • Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. 
  • Psychometric properties of a tool for measuring hormone-related symptoms in breast cancer survivors. 
  • Quantitative comparison of the inhibitory effects of GW5638 and tamoxifen on angiogenesis in the cornea pocket assay. 
  • Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. 
  • Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. 
  • Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. 
  • Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. 
  • Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. 
  • Relationship between tamoxifen use and high risk endometrial cancer histologic types. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic differences between clinically relevant SERM and between SERM/estrogen complexes. 
  • Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer. 
  • Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. 
  • Sclerosing mesenteritis involving the pancreas: a mimicker of pancreatic cancer. 
  • Screening experiments and the use of fractional factorial designs in behavioral intervention research. 
  • Selective estrogen receptor modulators (SERMs): A first step in the development of perfect hormone replacement therapy regimen. 
  • Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy. 
  • Serum cholesterol reduction with tamoxifen. 
  • Starting with the ABCs: Akt in breast cancer. 
  • Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. 
  • Structural requirements for high affinity ligand binding by estrogen receptors: a comparative analysis of truncated and full length estrogen receptors expressed in bacteria, yeast, and mammalian cells. 
  • Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. 
  • Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment. 
  • Systemic therapy for older women with breast cancer. 
  • TGF-β signalling is required for CD4⁺ T cell homeostasis but dispensable for regulatory T cell function. 
  • Tamoxifen Improves Glucose Tolerance in a Delivery-, Sex-, and Strain-Dependent Manner in Mice. 
  • Tamoxifen and tamoxifen ethyl bromide induce apoptosis in acutely damaged mammary epithelial cells through modulation of AKT activity. 
  • Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. 
  • Tamoxifen in postmenopausal women a safety perspective. 
  • Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. 
  • Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. 
  • Tamoxifen versus aromatase inhibitors for breast cancer prevention. 
  • Tamoxifen versus surgery in elderly patients with breast cancer. 
  • Tamoxifen-inducible gene deletion reveals a distinct cell type associated with trabecular bone, and direct regulation of PTHrP expression and chondrocyte morphology by Ihh in growth region cartilage. 
  • Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. 
  • Temporal control of gene deletion in sensory ganglia using a tamoxifen-inducible Advillin-Cre-ERT2 recombinase mouse. 
  • Temporally distinct and ligand-specific recruitment of nuclear receptor-interacting peptides and cofactors to subnuclear domains containing the estrogen receptor. 
  • Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. 
  • Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). 
  • Testing whether decision aids introduce cognitive biases: results of a randomized trial. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease. 
  • The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part II: Metastatic Disease. 
  • The distinct role of comparative risk perceptions in a breast cancer prevention program. 
  • The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. 
  • The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. 
  • The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. 
  • The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study. 
  • The importance of LAT in the activation, homeostasis, and regulatory function of T cells. 
  • The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. 
  • The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. 
  • Using Testlet Response Theory to analyze data from a survey of attitude change among breast cancer survivors. 
  • Variations in cancer care for adolescents and young adults (AYAs) with ductal carcinoma in situ. 
  • Volume of resection in patients treated with breast conservation for ductal carcinoma in situ. 
  • Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. 
  • Women's interest in chemoprevention for breast cancer. 
  • Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. 
  • [Primary chemotherapy in the treatment of breast cancer]. 
  • [The role of neo-adjuvant chemotherapy in breast cancers]. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
  • [Tumor regression as a prognostic factor in breast cancer]. 
  • β-Arrestin2 mediates progression of murine primary myelofibrosis. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Halabi, Susan, Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Cell Biology